Cargando…

Short-course PET based simultaneous integrated boost for locally advanced cervical cancer

BACKGROUND: Patients with large, locally advanced cervical cancers (LACC) are challenging to treat. The purpose of this work is to use 18F-FDG PET as planning basis for a short-course simultaneous integrated boost (SIB) in external beam radiotherapy of LACC in order to increase tumour shrinkage and...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnesen, Marius Røthe, Rekstad, Bernt Louni, Stokke, Caroline, Bruheim, Kjersti, Løndalen, Ayca Muftuler, Hellebust, Taran Paulsen, Malinen, Eirik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788887/
https://www.ncbi.nlm.nih.gov/pubmed/26968827
http://dx.doi.org/10.1186/s13014-016-0612-z
_version_ 1782420784367534080
author Arnesen, Marius Røthe
Rekstad, Bernt Louni
Stokke, Caroline
Bruheim, Kjersti
Løndalen, Ayca Muftuler
Hellebust, Taran Paulsen
Malinen, Eirik
author_facet Arnesen, Marius Røthe
Rekstad, Bernt Louni
Stokke, Caroline
Bruheim, Kjersti
Løndalen, Ayca Muftuler
Hellebust, Taran Paulsen
Malinen, Eirik
author_sort Arnesen, Marius Røthe
collection PubMed
description BACKGROUND: Patients with large, locally advanced cervical cancers (LACC) are challenging to treat. The purpose of this work is to use 18F-FDG PET as planning basis for a short-course simultaneous integrated boost (SIB) in external beam radiotherapy of LACC in order to increase tumour shrinkage and likelihood of local control. METHODS: Ten previously treated patients with LACC were included, all with pre-treatment FDG PET/CT images available. The FDG avid tumour volume, MTV(50), was dose escalated in silico by intensity modulated radiotherapy from the standard 1.8 Gy to 2.8 Gy per fraction for the 10 first fractions; a short-course SIB. For the 18 remaining external fractions, standard pelvic treatment followed to total PTV and MTV(50) doses of 50.4 Gy and 60.4 Gy, respectively. Photon and proton treatment were considered using volumetric modulated arc treatment (VMAT) and intensity-modulated proton therapy (IMPT), respectively. All treatment plans were generated using the Eclipse Treatment Planning System (TPS). The impact of tumour shrinkage on doses to organs at risk (OARs) was simulated in the TPS for the SIB plans. RESULTS: Dose escalation could be implemented using both VMAT and IMPT, with a D(98) ≥ 95 % for MTV(50) being achieved in all cases. The sum of the 10 fraction short-course SIB and subsequent 18 standard fractions was compared to the standard non-SIB approach by dose volume histogram (DVH) analysis. Only marginal increase of dose to OARs was found for both modalities and a small further increase estimated from tumour shrinkage. Most DVH parameters showed a mean difference below 2 %. IMPT had, compared to VMAT, reduced OAR doses in the low to intermediate dose range, but showed no additional advantage in dose escalation. CONCLUSIONS: Planning of dose escalation based on a FDG avid boost volume was here demonstrated feasible. The concept may allow time for enhanced tumour shrinkage before brachytherapy. Thus, this strategy may prove clinically valuable, in particular for patients with large tumours.
format Online
Article
Text
id pubmed-4788887
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47888872016-03-13 Short-course PET based simultaneous integrated boost for locally advanced cervical cancer Arnesen, Marius Røthe Rekstad, Bernt Louni Stokke, Caroline Bruheim, Kjersti Løndalen, Ayca Muftuler Hellebust, Taran Paulsen Malinen, Eirik Radiat Oncol Research BACKGROUND: Patients with large, locally advanced cervical cancers (LACC) are challenging to treat. The purpose of this work is to use 18F-FDG PET as planning basis for a short-course simultaneous integrated boost (SIB) in external beam radiotherapy of LACC in order to increase tumour shrinkage and likelihood of local control. METHODS: Ten previously treated patients with LACC were included, all with pre-treatment FDG PET/CT images available. The FDG avid tumour volume, MTV(50), was dose escalated in silico by intensity modulated radiotherapy from the standard 1.8 Gy to 2.8 Gy per fraction for the 10 first fractions; a short-course SIB. For the 18 remaining external fractions, standard pelvic treatment followed to total PTV and MTV(50) doses of 50.4 Gy and 60.4 Gy, respectively. Photon and proton treatment were considered using volumetric modulated arc treatment (VMAT) and intensity-modulated proton therapy (IMPT), respectively. All treatment plans were generated using the Eclipse Treatment Planning System (TPS). The impact of tumour shrinkage on doses to organs at risk (OARs) was simulated in the TPS for the SIB plans. RESULTS: Dose escalation could be implemented using both VMAT and IMPT, with a D(98) ≥ 95 % for MTV(50) being achieved in all cases. The sum of the 10 fraction short-course SIB and subsequent 18 standard fractions was compared to the standard non-SIB approach by dose volume histogram (DVH) analysis. Only marginal increase of dose to OARs was found for both modalities and a small further increase estimated from tumour shrinkage. Most DVH parameters showed a mean difference below 2 %. IMPT had, compared to VMAT, reduced OAR doses in the low to intermediate dose range, but showed no additional advantage in dose escalation. CONCLUSIONS: Planning of dose escalation based on a FDG avid boost volume was here demonstrated feasible. The concept may allow time for enhanced tumour shrinkage before brachytherapy. Thus, this strategy may prove clinically valuable, in particular for patients with large tumours. BioMed Central 2016-03-12 /pmc/articles/PMC4788887/ /pubmed/26968827 http://dx.doi.org/10.1186/s13014-016-0612-z Text en © Arnesen et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Arnesen, Marius Røthe
Rekstad, Bernt Louni
Stokke, Caroline
Bruheim, Kjersti
Løndalen, Ayca Muftuler
Hellebust, Taran Paulsen
Malinen, Eirik
Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
title Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
title_full Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
title_fullStr Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
title_full_unstemmed Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
title_short Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
title_sort short-course pet based simultaneous integrated boost for locally advanced cervical cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788887/
https://www.ncbi.nlm.nih.gov/pubmed/26968827
http://dx.doi.org/10.1186/s13014-016-0612-z
work_keys_str_mv AT arnesenmariusrøthe shortcoursepetbasedsimultaneousintegratedboostforlocallyadvancedcervicalcancer
AT rekstadberntlouni shortcoursepetbasedsimultaneousintegratedboostforlocallyadvancedcervicalcancer
AT stokkecaroline shortcoursepetbasedsimultaneousintegratedboostforlocallyadvancedcervicalcancer
AT bruheimkjersti shortcoursepetbasedsimultaneousintegratedboostforlocallyadvancedcervicalcancer
AT løndalenaycamuftuler shortcoursepetbasedsimultaneousintegratedboostforlocallyadvancedcervicalcancer
AT hellebusttaranpaulsen shortcoursepetbasedsimultaneousintegratedboostforlocallyadvancedcervicalcancer
AT malineneirik shortcoursepetbasedsimultaneousintegratedboostforlocallyadvancedcervicalcancer